The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Medicinal chemical properties of successful central nervous system drugs
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Lead- and drug-like compounds: the rule-of-five revolution
Lipinski, C. A. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.11.007 · Cited by 6,199
Partition coefficients and their uses
Leo, A., Hansch, C., & Elkins, D. (1971) · Chemical Reviews · doi:10.1021/cr60274a001 · Cited by 4,540
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Ertl, P., Rohde, B., & Selzer, P. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000942e · Cited by 3,084
Substituent constants for correlation analysis in chemistry and biology
Hansch, C. H., & Leo, A. J. (1979) · Medical Entomology and Zoology · Cited by 2,903
Abraham, M. H. (1993) · Chemical Society Reviews · doi:10.1039/cs9932200073 · Cited by 1,968
The Many Roles of Computation in Drug Discovery
Jorgensen, W. L. (2004) · Science · doi:10.1126/science.1096361 · Cited by 1,554
REDFERN, W., CARLSSON, L., DAVIS, A., LYNCH, W., MACKENZIE, I., PALETHORPE, S., SIEGL, P., STRANG, I., SULLIVAN, A., & WALLIS, R. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00846-5 · Cited by 1,532
Comprehensive medicinal chemistry
Timmerman, H., Bast, A., Van der Goot, H., Vermeulen, N. P. E., & Zeelen, F. J. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90535-z · Cited by 1,163
Levin, V. A. (1980) · Journal of Medicinal Chemistry · doi:10.1021/jm00180a022 · Cited by 813
Kelder, J., Grootenhuis, P. D. J., Bayada, D. M., Delbressine, L. P. C., & Ploemen, J.-P. (1999) · Pharmaceutical Research · doi:10.1023/a:1015040217741 · Cited by 813
Comprehensive Medicinal Chemistry
(1991) · Quantitative Structure-Activity Relationships · doi:10.1002/qsar.19910100410 · Cited by 745
Role of Pharmacokinetics and Metabolism in Drug Discovery and Development
Lin, J. H., & Lu, A. Y. H. (1997) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01340-1 · Cited by 708
Clark, D. E. (1999) · Journal of Pharmaceutical Sciences · doi:10.1021/js9804011 · Cited by 627
Doan, K. M. M., Humphreys, J. E., Webster, L. O., Wring, S. A., Shampine, L. J., Serabjit-Singh, C. J., Adkison, K. K., & Polli, J. W. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.039255 · Cited by 614
Property-Based Design: Optimization of Drug Absorption and Pharmacokinetics
van de Waterbeemd, H., Smith, D. A., Beaumont, K., & Walker, D. K. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm000407e · Cited by 599
van de Waterbeemd, H., Camenisch, G., Folkers, G., Chretien, J. R., & Raevsky, O. A. (1998) · Journal of Drug Targeting · doi:10.3109/10611869808997889 · Cited by 587
A Comparison of Physiochemical Property Profiles of Development and Marketed Oral Drugs
Wenlock, M. C., Austin, R. P., Barton, P., Davis, A. M., & Leeson, P. D. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm021053p · Cited by 546
Young, R. C., Mitchell, R. C., Brown, T. H., Ganellin, C. R., Griffiths, R., Jones, M., Rana, K. K., Saunders, D., & Smith, I. R. (1988) · Journal of Medicinal Chemistry · doi:10.1021/jm00398a028 · Cited by 521
Structure, function, and regulation of cellular tight junctions
Schneeberger, E. E., & Lynch, R. D. (1992) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1992.262.6.l647 · Cited by 518
Can We Learn To Distinguish between “Drug-like” and “Nondrug-like” Molecules?
Ajay, Walters, W. P., & Murcko, M. A. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970666c · Cited by 484
In silico prediction of blood–brain barrier permeation
Clark, D. E. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02827-7 · Cited by 483
CNS Drug Design Based on Principles of Blood‐Brain Barrier Transport
Pardridge, W. M. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70051781.x · Cited by 460
Hansch, C., Björkroth, J. P., & Leo, A. (1987) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600760902 · Cited by 438
Correlation of Drug Absorption with Molecular Surface Properties
Palm, K., Luthman, K., Unge, A.-L., Strandlund, G., & Artursson, P. (1996) · Journal of Pharmaceutical Sciences · doi:10.1021/js950285r · Cited by 412
Daly, J. W., Myers, C. W., & Whittaker, N. (1987) · Toxicon · doi:10.1016/0041-0101(87)90265-0 · Cited by 394
A Scoring Scheme for Discriminating between Drugs and Nondrugs
Sadowski, J., & Kubinyi, H. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9706776 · Cited by 392
Blood-Brain Barrier Permeation: Molecular Parameters Governing Passive Diffusion
Fischer, H., Gottschlich, R., & Seelig, A. (1998) · Journal of Membrane Biology · doi:10.1007/s002329900434 · Cited by 371
Bannon, A. W., Decker, M. W., Holladay, M. W., Curzon, P., Donnelly-Roberts, D., Puttfarcken, P. S., Bitner, R. S., Diaz, A., Dickenson, A. H., Porsolt, R. D., et al. (1998) · Science · doi:10.1126/science.279.5347.77 · Cited by 368
Characteristic Physical Properties and Structural Fragments of Marketed Oral Drugs
Vieth, M., Siegel, M. G., Higgs, R. E., Watson, I. A., Robertson, D. H., Savin, K. A., Durst, G. L., & Hipskind, P. A. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030267j · Cited by 359
Time-Related Differences in the Physical Property Profiles of Oral Drugs
Leeson, P. D., & Davis, A. M. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049717d · Cited by 326
Designing Libraries with CNS Activity
Ajay, Bemis, G. W., & Murcko, M. A. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990017w · Cited by 316
Pharmaceutical profiling in drug discovery
Kerns, E. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02649-7 · Cited by 288
Recanatini, M., Poluzzi, E., Masetti, M., Cavalli, A., & De Ponti, F. (2005) · Medicinal Research Reviews · doi:10.1002/med.20019 · Cited by 285
Progress in predicting human ADME parameters in silico
Ekins, S., Waller, C. L., Swaan, P. W., Cruciani, G., Wrighton, S. A., & Wikel, J. H. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00109-x · Cited by 274
From Knowing to Controlling: A Path from Genomics to Drugs Using Small Molecule Probes
Strausberg, R. L., & Schreiber, S. L. (2003) · Science · doi:10.1126/science.1083395 · Cited by 260
PERSPECTIVE: THE SMALL-MOLECULE APPROACH TO BIOLOGY
SCHREIBER (2003) · Chemical & Engineering News Archive · doi:10.1021/cen-v081n009.p051 · Cited by 246
Parabolic dependence of drug action upon lipophilic character as revealed by a study of hypnotics
Hansch, C., Steward, A. R., Anderson, S. M., & Bentley, D. L. (1968) · Journal of Medicinal Chemistry · doi:10.1021/jm00307a001 · Cited by 233
Cytochrome P450 in Silico: An Integrative Modeling Approach
de Graaf, C., Vermeulen, N. P. E., & Feenstra, K. A. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040180d · Cited by 201
Palm, K., Luthman, K., Ros, J., Gråsjö, J., & Artursson, P. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35123-7 · Cited by 173
Partitioning of Ionizing Molecules between Aqueous Buffers and Phospholipid Vesicles
Austin, R. P., Davis, A. M., & Manners, C. N. (1995) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600841008 · Cited by 171
Testa, B., Krämer, S. D., Wunderli‐Allenspach, H., & Folkers, G. (2006) · Cited by 166
A New Look at Lipid-Membrane Structure in Relation to Drug Research
Mouritsen, O. G., & Jørgensen, K. (1998) · Pharmaceutical Research · doi:10.1023/a:1011986613392 · Cited by 159
Graff, C. L., & Pollack, G. M. (2004) · Current Drug Metabolism · doi:10.2174/1389200043489126 · Cited by 147
Adenot, M., & Lahana, R. (2004) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci034205d · Cited by 145
Iyer, M., Mishra, R. K., Han, Y., & Hopfinger, A. J. (2002) · Pharmaceutical Research · doi:10.1023/a:1020792909928 · Cited by 142
Predicting undesirable drug interactions with promiscuous proteins in silico
Ekins, S. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(03)03008-3 · Cited by 134
Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs
Faassen, F. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00372-7 · Cited by 132
T-Type Ca2+ Channels and Pharmacological Blockade: Potential Pathophysiological Relevance
Ertel, S. I., Ertel, E. A., & Clozel, J. (1997) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1007706022381 · Cited by 127
Liljebris, C., Larsen, S. D., Ogg, D., Palazuk, B. J., & Bleasdale, J. E. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm011100y · Cited by 113
The blood-brain barrier and neurotherapeutics
Pardridge, W. M. (2004) · NeuroRx · doi:10.1602/neurorx.2.1.1 · Cited by 111
ter Laak, A., Tsai, R., den Kelder, G. M. D.-O., Carrupt, P., Testa, B., & Timmerman, H. (1994) · European Journal of Pharmaceutical Sciences · doi:10.1016/0928-0987(94)00065-4 · Cited by 106
Goodwin, J. T., Conradi, R. A., Ho, N. F. H., & Burton, P. S. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010253i · Cited by 104
Österberg, T., & Norinder, U. (2000) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000065l · Cited by 99
Assessment of Blood-Brain Barrier Penetration: In Silico, In Vitro and In Vivo
Feng, B. S. P. M. R. (2002) · Current Drug Metabolism · doi:10.2174/1389200023337063 · Cited by 95
In Silico Prediction Models for Blood-Brain Barrier Permeation
Ecker, G. F., & Noe, C. R. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043365071 · Cited by 86
QSAR studies on drugs acting at the central nervous system
Gupta, S. P. (1989) · Chemical Reviews · doi:10.1021/cr00098a007 · Cited by 86
Waterbeemd, H. V. D. (1998) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(98)00051-7 · Cited by 78
Molecular and Pharmacokinetic Properties of 222 Commercially Available Oral Drugs in Humans.
Sakaeda, T., Okamura, N., Nagata, S., Yagami, T., Horinouchi, M., Okumura, K., Yamashita, F., & Hashida, M. (2001) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.24.935 · Cited by 67
Lipophilicity and Other Parameters Affecting Brain Penetration
Atkinson, F., Cole, S. M., Green, C. E., & Waterbeemd, H. V. D. (2002) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/1568015023358058 · Cited by 62
Pan, D., Iyer, M., Liu, J., Li, Y., & Hopfinger, A. J. (2004) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci0498057 · Cited by 49
Dipole moment in relation to hydrogen receptor histamine antagonist activity for cimetidine analogs
Young, R. C., Durant, G. J., Emmett, J. C., Ganellin, C. R., Graham, M. J., Mitchell, R. C., Prain, H. D., & Roantree, M. L. (1986) · Journal of Medicinal Chemistry · doi:10.1021/jm00151a007 · Cited by 45
Raub, T. J., Lutzke, B. S., Andrus, P. K., Sawada, G. A., & Staton, B. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-44961-6_16 · Cited by 35
Blood-Brain Barrier Penetration and Drug Development from an Industrial Point of View
Mertsch, K., & Maas, J. (2002) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/1568015023358067 · Cited by 35
Qsar of P450 Oxidation: On the Value of ComparingkcatandKmwithKcat/Km
Gao, H., & Hansch, C. H. (1996) · Drug Metabolism Reviews · doi:10.3109/03602539608994017 · Cited by 29
Comparative Anatomy, Physiology and In Vitro Models of the Blood-Brain and Blood-Retina Barrier
Schlosshauer, B., & Steuer, H. (2002) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/1568015023357978 · Cited by 23
Williams, M. J., Coyle, J. T., Shaikh, S., & Decker, M. W. (2001) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(01)36041-4 · Cited by 13
In Vitro Models for Early Studies of Drug Metabolism
Lin, J. H., & Rodrigues, A. D. (2001) · doi:10.1002/9783906390437.ch14 · Cited by 12
Computational Approaches for the Prediction of Blood-Brain Barrier Permeation
Sippl, W. (2002) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/1568015023357996 · Cited by 11
Cited by
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
Lovering, F., Bikker, J., & Humblet, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901241e · Cited by 4,495
Synthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martinez, J., & Khrestchatisky, M. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,476
Blood–brain barrier structure and function and the challenges for CNS drug delivery
Abbott, N. J. (2013) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-013-9608-0 · Cited by 909
A perspective on multi‐target drug discovery and design for complex diseases
Ramsay, R. R., Popovic‐Nikolic, M. R., Nikolic, K., Uliassi, E., & Bolognesi, M. L. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0181-2 · Cited by 718
Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
Metadata
- Authors
- Pajouhesh, H., & Lenz, G. R.
- Venue
- NeuroRX
- Published
- 2005-10
- Volume
- 2
- Issue
- 4
- Pages
- 541-553
- ISSN
- 1545-5343 (ISSN-L)
- OpenAlex
- W1971513938
- Cited by
- 1,535
- References
- 72
- FWCI
- 5.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.